Atlas Trials

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Clinical trial NCT05877859 · RECRUITING

Trial details

NCT number
NCT05877859
Sponsor
Emory University
Status
RECRUITING
Study type
OBSERVATIONAL
Breast Cancer Triple NegativeBreast Cancer Stage IIBreast Cancer Stage IIIBreast Cancer Invasive
Start date
2023-05-30
Primary completion
2027-02-20
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.